187 related articles for article (PubMed ID: 29734046)
1. Impact of neoadjuvant chemotherapy and pathological complete response on eligibility for breast-conserving surgery in patients with early breast cancer: A meta-analysis.
Criscitiello C; Golshan M; Barry WT; Viale G; Wong S; Santangelo M; Curigliano G
Eur J Cancer; 2018 Jul; 97():1-6. PubMed ID: 29734046
[TBL] [Abstract][Full Text] [Related]
2. The impact of neoadjuvant systemic therapy on breast conservation rates in patients with HER2-positive breast cancer: Surgical results from a phase II randomized controlled trial.
Yamaguchi T; Hozumi Y; Sagara Y; Takahashi M; Yoneyama K; Fujisawa T; Osumi S; Akabane H; Nishimura R; Mieno MN; Mukai H
Surg Oncol; 2021 Mar; 36():51-55. PubMed ID: 33310293
[TBL] [Abstract][Full Text] [Related]
3. Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II-III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance).
Golshan M; Cirrincione CT; Sikov WM; Carey LA; Berry DA; Overmoyer B; Henry NL; Somlo G; Port E; Burstein HJ; Hudis C; Winer E; Ollila DW;
Breast Cancer Res Treat; 2016 Nov; 160(2):297-304. PubMed ID: 27704226
[TBL] [Abstract][Full Text] [Related]
4. Impact of neoadjuvant chemotherapy in stage II-III triple negative breast cancer on eligibility for breast-conserving surgery and breast conservation rates: surgical results from CALGB 40603 (Alliance).
Golshan M; Cirrincione CT; Sikov WM; Berry DA; Jasinski S; Weisberg TF; Somlo G; Hudis C; Winer E; Ollila DW;
Ann Surg; 2015 Sep; 262(3):434-9; discussion 438-9. PubMed ID: 26222764
[TBL] [Abstract][Full Text] [Related]
5. Loco-regional control after neo-adjuvant chemotherapy and conservative treatment for locally advanced breast cancer patients.
Levy A; Borget I; Bahri M; Arnedos M; Rivin E; Vielh P; Balleyguier C; Rimareix F; Bourgier C
Breast J; 2014; 20(4):381-7. PubMed ID: 24890310
[TBL] [Abstract][Full Text] [Related]
6. Breast Conservation After Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: Surgical Results From the BrighTNess Randomized Clinical Trial.
Golshan M; Loibl S; Wong SM; Houber JB; O'Shaughnessy J; Rugo HS; Wolmark N; McKee MD; Maag D; Sullivan DM; Metzger-Filho O; Von Minckwitz G; Geyer CE; Sikov WM; Untch M
JAMA Surg; 2020 Mar; 155(3):e195410. PubMed ID: 31913413
[TBL] [Abstract][Full Text] [Related]
7. Do MRI and mammography reliably identify candidates for breast conservation after neoadjuvant chemotherapy?
Jochelson MS; Lampen-Sachar K; Gibbons G; Dang C; Lake D; Morris EA; Morrow M
Ann Surg Oncol; 2015 May; 22(5):1490-5. PubMed ID: 25777093
[TBL] [Abstract][Full Text] [Related]
8. Breast-conserving therapy vs mastectomy in early-stage breast cancer: a meta-analysis of 10-year survival.
Morris AD; Morris RD; Wilson JF; White J; Steinberg S; Okunieff P; Arriagada R; Lê MG; Blichert-Toft M; van Dongen JA
Cancer J Sci Am; 1997; 3(1):6-12. PubMed ID: 9072310
[TBL] [Abstract][Full Text] [Related]
9. Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.
Iwata H; Sato N; Masuda N; Nakamura S; Yamamoto N; Kuroi K; Kurosumi M; Tsuda H; Akiyama F; Ohashi Y; Toi M
Jpn J Clin Oncol; 2011 Jul; 41(7):867-75. PubMed ID: 21719750
[TBL] [Abstract][Full Text] [Related]
10. Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study.
von Minckwitz G; Kümmel S; Vogel P; Hanusch C; Eidtmann H; Hilfrich J; Gerber B; Huober J; Costa SD; Jackisch C; Loibl S; Mehta K; Kaufmann M;
J Natl Cancer Inst; 2008 Apr; 100(8):552-62. PubMed ID: 18398094
[TBL] [Abstract][Full Text] [Related]
11. Conversion rate from mastectomy to breast conservation after neoadjuvant dual target therapy for HER2-positive breast cancer in the Asian population.
Chang YK; Co M; Kwong A
Breast Cancer; 2020 May; 27(3):456-463. PubMed ID: 31916189
[TBL] [Abstract][Full Text] [Related]
12. Current strategy for triple-negative breast cancer: appropriate combination of surgery, radiation, and chemotherapy.
Yagata H; Kajiura Y; Yamauchi H
Breast Cancer; 2011 Jul; 18(3):165-73. PubMed ID: 21290263
[TBL] [Abstract][Full Text] [Related]
13. Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of randomized controlled trials.
Solinas C; Ceppi M; Lambertini M; Scartozzi M; Buisseret L; Garaud S; Fumagalli D; de Azambuja E; Salgado R; Sotiriou C; Willard-Gallo K; Ignatiadis M
Cancer Treat Rev; 2017 Jun; 57():8-15. PubMed ID: 28525810
[TBL] [Abstract][Full Text] [Related]
14. Impact of chemotherapy sequencing on local-regional failure risk in breast cancer patients undergoing breast-conserving therapy.
Mittendorf EA; Buchholz TA; Tucker SL; Meric-Bernstam F; Kuerer HM; Gonzalez-Angulo AM; Bedrosian I; Babiera GV; Hoffman K; Yi M; Ross MI; Hortobagyi GN; Hunt KK
Ann Surg; 2013 Feb; 257(2):173-9. PubMed ID: 23291658
[TBL] [Abstract][Full Text] [Related]
15. Oncologic safety of breast-conserving surgery compared to mastectomy in patients receiving neoadjuvant chemotherapy for locally advanced breast cancer.
Cho JH; Park JM; Park HS; Park S; Kim SI; Park BW
J Surg Oncol; 2013 Dec; 108(8):531-6. PubMed ID: 24115142
[TBL] [Abstract][Full Text] [Related]
16. A prospective trial of preoperative chemotherapy in resectable breast cancer: predictors of breast-conservation therapy feasibility.
Newman LA; Buzdar AU; Singletary SE; Kuerer HM; Buchholz T; Ames FC; Ross MI; Hunt KK
Ann Surg Oncol; 2002 Apr; 9(3):228-34. PubMed ID: 11923128
[TBL] [Abstract][Full Text] [Related]
17. Dose-dense primary chemotherapy, as part of multidisciplinary treatment, for inoperable stage III B breast cancer--long-term results of a phase II trial.
Massidda B; Atzori F; Scanu A; Contu A; Farris A; Catino AM; Palmeri S; Minerba L; Ionta MT
Oncology; 2007; 72(1-2):17-26. PubMed ID: 17998786
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant chemotherapy increases the rate of breast conservation in lobular-type breast cancer patients.
Fitzal F; Mittlboeck M; Steger G; Bartsch R; Rudas M; Dubsky P; Riedl O; Jakesz R; Gnant M
Ann Surg Oncol; 2012 Feb; 19(2):519-26. PubMed ID: 21743980
[TBL] [Abstract][Full Text] [Related]
19. Breast-conserving therapy after neoadjuvant chemotherapy: long-term results.
Beriwal S; Schwartz GF; Komarnicky L; Garcia-Young JA
Breast J; 2006; 12(2):159-64. PubMed ID: 16509842
[TBL] [Abstract][Full Text] [Related]
20. De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET.
Harbeck N; Gluz O; Christgen M; Kates RE; Braun M; Küemmel S; Schumacher C; Potenberg J; Kraemer S; Kleine-Tebbe A; Augustin D; Aktas B; Forstbauer H; Tio J; von Schumann R; Liedtke C; Grischke EM; Schumacher J; Wuerstlein R; Kreipe HH; Nitz UA
J Clin Oncol; 2017 Sep; 35(26):3046-3054. PubMed ID: 28682681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
